Switch theme
Sign up to access all valuation multiples
Kyverna Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing cell therapies for patients suffering from autoimmune diseases. Its product, KYV-101, is an autologous CD19 CAR T-cell product candidate made from an underlying chimeric antigen receptor, or CAR. It is also developing KYV-201, an allogeneic therapy containing the same CAR as KYV-101, to develop it in multiple autoimmune diseases.
2018
112
Last FY Revenue n/a
LTM EBITDA -$160M
-$125M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Kyverna Therapeutics has a last 12-month revenue (LTM) of n/a and a last 12-month EBITDA of -$160M.
In the most recent fiscal year, Kyverna Therapeutics achieved revenue of n/a and an EBITDA of -$125M.
Kyverna Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Kyverna Therapeutics valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | n/a | XXX | n/a | XXX | XXX | XXX |
| Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA | -$160M | XXX | -$125M | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBIT | -$159M | XXX | -$143M | XXX | XXX | XXX |
| EBIT Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| Net Profit | -$145M | XXX | -$127M | XXX | XXX | XXX |
| Net Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Kyverna Therapeutics's stock price is $3.
Kyverna Therapeutics has current market cap of $111M, and EV of -$125M.
See Kyverna Therapeutics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| -$125M | $111M | XXX | XXX | XXX | XXX | $-3.49 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Kyverna Therapeutics has market cap of $111M and EV of -$125M.
Kyverna Therapeutics's trades at n/a EV/Revenue multiple, and 1.0x EV/EBITDA.
Equity research analysts estimate Kyverna Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Kyverna Therapeutics has a P/E ratio of -0.8x.
See valuation multiples for Kyverna Therapeutics and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $111M | XXX | $111M | XXX | XXX | XXX |
| EV (current) | -$125M | XXX | -$125M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | n/a | XXX | XXX | XXX |
| EV/EBITDA | 0.8x | XXX | 1.0x | XXX | XXX | XXX |
| EV/EBIT | 0.8x | XXX | 0.9x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | -0.8x | XXX | -0.9x | XXX | XXX | XXX |
| EV/FCF | 0.9x | XXX | 1.1x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialKyverna Therapeutics's revenue per employee in the last FY averaged n/a, while opex per employee averaged $1.3M for the same period.
Kyverna Therapeutics's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Kyverna Therapeutics's rule of X is n/a (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Kyverna Therapeutics and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Growth | 26% | XXX | 79% | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $1.3M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Kyverna Therapeutics acquired XXX companies to date.
Last acquisition by Kyverna Therapeutics was XXXXXXXX, XXXXX XXXXX XXXXXX . Kyverna Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Kyverna Therapeutics founded? | Kyverna Therapeutics was founded in 2018. |
| Where is Kyverna Therapeutics headquartered? | Kyverna Therapeutics is headquartered in United States of America. |
| How many employees does Kyverna Therapeutics have? | As of today, Kyverna Therapeutics has 112 employees. |
| Who is the CEO of Kyverna Therapeutics? | Kyverna Therapeutics's CEO is Mr. Warner Weston Biddle. |
| Is Kyverna Therapeutics publicy listed? | Yes, Kyverna Therapeutics is a public company listed on NAS. |
| What is the stock symbol of Kyverna Therapeutics? | Kyverna Therapeutics trades under KYTX ticker. |
| When did Kyverna Therapeutics go public? | Kyverna Therapeutics went public in 2024. |
| Who are competitors of Kyverna Therapeutics? | Similar companies to Kyverna Therapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Kyverna Therapeutics? | Kyverna Therapeutics's current market cap is $111M |
| Is Kyverna Therapeutics profitable? | Yes, Kyverna Therapeutics is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Kyverna Therapeutics? | Kyverna Therapeutics's last 12 months EBITDA is -$160M. |
| What is the current EV/EBITDA multiple of Kyverna Therapeutics? | Current EBITDA multiple of Kyverna Therapeutics is 0.8x. |
| What is the current FCF of Kyverna Therapeutics? | Kyverna Therapeutics's last 12 months FCF is -$136M. |
| What is the current EV/FCF multiple of Kyverna Therapeutics? | Current FCF multiple of Kyverna Therapeutics is 0.9x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
